

Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Original) A packaged medicinal product having extended shelf-life comprising:
 - (a) a medicinal preparation; and
 - (b) a plastic container having a fluorinated barrier layer on a surface of the body wall, wherein the body of the container is fill with the medicinal preparation.
2. (Original) A packaged medicinal product according to claim 1, wherein the medicinal preparation is a liquid.
3. (Original) A packaged medicinal product according to claim 2, wherein the medicinal preparation comprises a highly potent ingredient.
4. (Original) A packaged medicinal product according to claim 3, wherein the highly potent ingredient is a prostaglandin.
5. (Original) A packaged medicinal product according to claim 1, wherein the container is made of materials comprising LDPE, HDPE or PP.
6. (Original) A packaged medicinal product according to claim 5, wherein the container is a small volume bottle.
7. (Original) A packaged medicinal product according to claim 6, wherein the medicinal preparation comprises a prostaglandin.
8. (Original) A packaged medicinal product according to claim 7, which is for ophthalmic use.
9. (Original) A method of packaging a medicinal preparation, said method comprising the steps of:
 - (a) providing a plastic container having a fluorinated barrier layer on a surface of its body wall; and
 - (b) filling the container body with the medicinal preparation.
10. (Original) The method according to claim 9, wherein the medicinal preparation is a liquid.

11. (Original) The method according to claim 10, wherein the medicinal preparation comprises a highly potent ingredient.

12. (Original) The method according to claim 11, wherein the highly potent ingredient is a prostaglandin.

13. (Currently Amended) The method according to claim 9, wherein the container is made of materials comprising LDPE, PP, or HDPE.

14. (Original) The method according to claim 13, wherein the container is a small volume bottle.

15. (Original) The method according to claim 14, wherein the medicinal preparation comprises a prostaglandin.

16. (Original) The method according to claim 15, wherein the medicinal preparation is for ophthalmic use.

17. (Original) A method of increasing the stability of a liquid medicinal preparation, said method comprising packaging the liquid medicinal preparation in a plastic container having a fluorinated barrier layer on a surface of the container body wall.

18. (Currently Amended) The method according to claim 17, wherein the plastic container is made of materials comprising LDPE, PP, or HDPE.

19. (Original) The method according to claim 18, wherein the liquid medicinal preparation comprises a highly potent ingredient.

20. (Original) The method according to claim 19, wherein the highly potent ingredient is a prostaglandin.

21. (Original) The method according to claim 20, wherein the medicinal preparation is for ophthalmic use.

22. (Original) A method of preventing loss of an ingredient in a liquid medicinal preparation through the wall of a plastic container which contains the medicinal preparations, said

method comprising packaging the medicinal preparation in the plastic container said container having has a fluorinated barrier layer on a surface of the container body wall.

23. (Currently Amended) The method according to claim 22, wherein the plastic container is made of materials comprising LDPE, PP, or HDPE.

24. (Original) The method according to claim 22, wherein the liquid medicinal preparation comprises a highly potent ingredient.

25. (Original) The method according to claim 24, wherein the highly potent ingredient is a prostaglandin.

26. (Original) The method according to claim 25, wherein the medicinal preparation is for ophthalmic use.

27. (Original) The method according to claim 22, wherein the container has a fluorinated barrier layer on the inside surface of the container body wall.

28. (Original) A method of reducing transfer of an impurity into a liquid medicinal preparation upon storage, comprising packaging the liquid medicinal preparation in a plastic container said container having a fluorinated barrier layer on a surface of the container body wall.

29. (Currently Amended) The method according to claim 28, wherein the plastic container is made of materials comprising LDPE, PP, or HDPE.

30. (Original) The method according to claim 28, wherein the liquid medicinal preparation comprises a highly potent ingredient.

31. (Original) The method according to claim 30, wherein the highly potent ingredient is a prostaglandin.

32. (Original) The method according to claim 31, wherein the medicinal preparation is for ophthalmic use.

33. (Original) The method according to claim 28, wherein the container has a fluorinated barrier layer on the inside surface of the container body wall.